{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:44:30Z","timestamp":1759963470302,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG2K0081-83","CMRPG3M1261-1263"],"award-info":[{"award-number":["CMRPG2K0081-83","CMRPG3M1261-1263"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2314-B-182A-117"],"award-info":[{"award-number":["111-2314-B-182A-117"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03873-0","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T12:09:20Z","timestamp":1750507760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HBx mutant-regulated RPL13AP25 mediates suboptimal virological response to entecavir\u2002and HCC progression"],"prefix":"10.1186","volume":"25","author":[{"given":"Yang-Hsiang","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-De","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Huei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Heng","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"2","key":"3873_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.livres.2024.05.004","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed W, El-Kassas M. Hepatitis B virus as a risk factor for hepatocellular carcinoma: there is still much work to do. Liver Res. 2024;8(2):83\u201390.","journal-title":"Liver Res"},{"key":"3873_CR2","doi-asserted-by":"crossref","unstructured":"Ignat MD, Balta AAS, Barbu RE, Draganescu ML, Nechita L, Voinescu DC et al. Antiviral therapy of chronic hepatitis B virus between present and future. J Clin Med. 2024;13(7).","DOI":"10.3390\/jcm13072055"},{"key":"3873_CR3","doi-asserted-by":"crossref","unstructured":"Lumley SF, Mokaya J, Maponga TG, Kramvis A, Dusheiko G, Irving W et al. Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field. Lancet Microbe. 2025;101076.","DOI":"10.1016\/j.lanmic.2025.101076"},{"issue":"6","key":"3873_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping nucs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","journal-title":"J Hepatol"},{"issue":"5","key":"3873_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2024.12.004","volume":"82","author":"GL Wong","year":"2025","unstructured":"Wong GL, Lemoine M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines. J Hepatol. 2025;82(5):918\u201325.","journal-title":"J Hepatol"},{"issue":"5","key":"3873_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031\u201348.","journal-title":"Hepatol Int"},{"issue":"5","key":"3873_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4254\/wjh.v14.i5.866","volume":"14","author":"C Bianca","year":"2022","unstructured":"Bianca C, Sidhartha E, Tiribelli C, El-Khobar KE, Sukowati CHC. Role of hepatitis B virus in development of hepatocellular carcinoma: focus on covalently closed circular DNA. World J Hepatol. 2022;14(5):866\u201384.","journal-title":"World J Hepatol"},{"issue":"1","key":"3873_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12929-024-01063-0","volume":"31","author":"YD Chu","year":"2024","unstructured":"Chu YD, Chen MC, Yeh CT, Lai MW. Hijacking host extracellular vesicle machinery by hepatotropic viruses: current Understandings and future prospects. J Biomed Sci. 2024;31(1):97.","journal-title":"J Biomed Sci"},{"key":"3873_CR9","doi-asserted-by":"publisher","first-page":"795388","DOI":"10.3389\/fmicb.2021.795388","volume":"12","author":"YP Qin","year":"2021","unstructured":"Qin YP, Yu HB, Yuan SY, Yang Z, Ren F, Wang Q, et al. KAT2A promotes hepatitis B virus transcription and replication through epigenetic regulation of CccDNA minichromosome. Front Microbiol. 2021;12:795388.","journal-title":"Front Microbiol"},{"issue":"2","key":"3873_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/hep.29133","volume":"66","author":"W Zhang","year":"2017","unstructured":"Zhang W, Chen J, Wu M, Zhang X, Zhang M, Yue L, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology. 2017;66(2):398\u2013415.","journal-title":"Hepatology"},{"issue":"47","key":"3873_CR11","doi-asserted-by":"publisher","first-page":"19975","DOI":"10.1073\/pnas.0908365106","volume":"106","author":"L Belloni","year":"2009","unstructured":"Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of CccDNA function. Proc Natl Acad Sci U S A. 2009;106(47):19975\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3873_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cmi.2018.11.017","volume":"25","author":"R Salpini","year":"2019","unstructured":"Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, et al. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin Microbiol Infect. 2019;25(7):906. e1- e7.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"3873_CR13","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1111\/liv.15348","volume":"42","author":"KC Chang","year":"2022","unstructured":"Chang KC, Chua HH, Chen YH, Tsuei DJ, Lee MH, Chiang CL, et al. Hepatitis B virus X gene impacts on the innate immunity and immune-tolerant phase in chronic hepatitis B virus infection. Liver Int. 2022;42(10):2154\u201366.","journal-title":"Liver Int"},{"issue":"7","key":"3873_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1541-7786.MCR-18-1127","volume":"17","author":"AP Chiu","year":"2019","unstructured":"Chiu AP, Tschida BR, Sham TT, Lo LH, Moriarity BS, Li XX, et al. HBx-K130M\/V131I promotes liver Cancer in Transgenic mice via AKT\/FOXO1 signaling pathway and arachidonic acid metabolism. Mol Cancer Res. 2019;17(7):1582\u201393.","journal-title":"Mol Cancer Res"},{"key":"3873_CR15","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.1016\/j.micpath.2021.105136","volume":"159","author":"C Zhang","year":"2021","unstructured":"Zhang C, Xiao C, Ren G, Cai D, Long L, Li J, et al. C-terminal-truncated hepatitis B virus X protein promotes hepatocarcinogenesis by activating the MAPK pathway. Microb Pathog. 2021;159:105136.","journal-title":"Microb Pathog"},{"key":"3873_CR16","doi-asserted-by":"crossref","unstructured":"Lin YH, Yeh CT, Chen CY, Lin KH. Pseudogene: relevant or irrelevant? Biomed J. 2024;100790.","DOI":"10.1016\/j.bj.2024.100790"},{"key":"3873_CR17","doi-asserted-by":"publisher","first-page":"155014","DOI":"10.1016\/j.prp.2023.155014","volume":"253","author":"B Karimi","year":"2024","unstructured":"Karimi B, Mokhtari K, Rozbahani H, Peymani M, Nabavi N, Entezari M, et al. Pathological roles of MiRNAs and pseudogene-derived LncRNAs in human cancers, and their comparison as prognosis\/diagnosis biomarkers. Pathol Res Pract. 2024;253:155014.","journal-title":"Pathol Res Pract"},{"key":"3873_CR18","doi-asserted-by":"crossref","unstructured":"Lee J, Hwang JH, Chun H, Woo W, Oh S, Choi J et al. PLEKHA8P1 promotes tumor progression and indicates poor prognosis of liver Cancer. Int J Mol Sci. 2021;22(14).","DOI":"10.3390\/ijms22147614"},{"issue":"4","key":"3873_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41419-020-2469-1","volume":"11","author":"MZ Wu","year":"2020","unstructured":"Wu MZ, Fu T, Chen JX, Lin YY, Yang JE, Zhuang SM. LncRNA GOLGA2P10 is induced by PERK\/ATF4\/CHOP signaling and protects tumor cells from ER stress-induced apoptosis by regulating Bcl-2 family members. Cell Death Dis. 2020;11(4):276.","journal-title":"Cell Death Dis"},{"key":"3873_CR20","doi-asserted-by":"crossref","unstructured":"Hsu CW, Chu YD, Lai MW, Lin CL, Liang KH, Lin YH et al. Hepatitis B virus covalently closed circular DNA predicts postoperative liver Cancer metastasis independent of virological suppression. Cancers (Basel). 2021;13(3).","DOI":"10.3390\/cancers13030538"},{"issue":"11","key":"3873_CR21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1136\/gutjnl-2019-319637","volume":"69","author":"D Salerno","year":"2020","unstructured":"Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, Paturel A, et al. Hepatitis B protein HBx binds the DLEU2 LncRNA to sustain CccDNA and host cancer-related gene transcription. Gut. 2020;69(11):2016\u201324.","journal-title":"Gut"},{"issue":"W1","key":"3873_CR22","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3873_CR23","doi-asserted-by":"publisher","first-page":"e28967","DOI":"10.1002\/jmv.28967","volume":"95","author":"Y Qu","year":"2023","unstructured":"Qu Y, Wang W, Xiao MZX, Zheng Y, Liang Q. The interplay between lipid droplets and virus infection. J Med Virol. 2023;95(7):e28967.","journal-title":"J Med Virol"},{"issue":"Pt 3","key":"3873_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.semcancer.2022.04.006","volume":"86","author":"A Rubio","year":"2022","unstructured":"Rubio A, Garland GD, Sfakianos A, Harvey RF, Willis AE. Aberrant protein synthesis and cancer development: the role of canonical eukaryotic initiation, elongation and termination factors in tumorigenesis. Semin Cancer Biol. 2022;86(Pt 3):151\u201365.","journal-title":"Semin Cancer Biol"},{"key":"3873_CR25","doi-asserted-by":"publisher","first-page":"1076855","DOI":"10.3389\/fonc.2023.1076855","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, An Y, Tan M, Xie D, Liu L, Xu B. Biological functions and research progress of eIF4E. Front Oncol. 2023;13:1076855.","journal-title":"Front Oncol"},{"issue":"3","key":"3873_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1021\/acsptsci.4c00674","volume":"8","author":"RL O\u2019Rourke","year":"2025","unstructured":"O\u2019Rourke RL, Garner AL. Chemical probes for studying the eukaryotic translation initiation factor 4E (eIF4E)-Regulated translatome in Cancer. ACS Pharmacol Transl Sci. 2025;8(3):621\u201335.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3873_CR27","doi-asserted-by":"crossref","unstructured":"Bou Antoun N, Chioni AM. Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci. 2023;24(15).","DOI":"10.3390\/ijms241512222"},{"issue":"1","key":"3873_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21505594.2022.2093444","volume":"13","author":"S Phillips","year":"2022","unstructured":"Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence. 2022;13(1):1111\u201332.","journal-title":"Virulence"},{"key":"3873_CR29","doi-asserted-by":"crossref","unstructured":"Saeed U, Kim J, Piracha ZZ, Kwon H, Jung J, Chwae YJ et al. Parvulin 14 and parvulin 17 bind to HBx and CccDNA and upregulate hepatitis B virus replication from CccDNA to virion in an HBx-Dependent manner. J Virol. 2019;93(6).","DOI":"10.1128\/JVI.01840-18"},{"key":"3873_CR30","doi-asserted-by":"publisher","first-page":"701061","DOI":"10.3389\/fmed.2021.701061","volume":"8","author":"R Chen","year":"2021","unstructured":"Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, et al. Suboptimal response to Tenofovir Alafenamide in two patients with HBeAg-Positive hepatitis B: A case report. Front Med (Lausanne). 2021;8:701061.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3873_CR31","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/hep.30423","volume":"69","author":"CL Lin","year":"2019","unstructured":"Lin CL, Chu YD, Yeh CT. Emergence of Oncogenic-Enhancing hepatitis B virus X gene mutants in patients receiving suboptimal Entecavir treatment. Hepatology. 2019;69(5):2292\u20136.","journal-title":"Hepatology"},{"issue":"1","key":"3873_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/hep.25979","volume":"57","author":"KM Sze","year":"2013","unstructured":"Sze KM, Chu GK, Lee JM, Ng IO. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun\/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology. 2013;57(1):131\u20139.","journal-title":"Hepatology"},{"issue":"Pt 3","key":"3873_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1099\/vir.0.070680-0","volume":"96","author":"I Quetier","year":"2015","unstructured":"Quetier I, Brezillon N, Revaud J, Ahodantin J, DaSilva L, Soussan P, et al. C-terminal-truncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis. J Gen Virol. 2015;96(Pt 3):614\u201325.","journal-title":"J Gen Virol"},{"issue":"17","key":"3873_CR34","doi-asserted-by":"publisher","first-page":"24005","DOI":"10.18632\/oncotarget.8209","volume":"7","author":"KY Ng","year":"2016","unstructured":"Ng KY, Chai S, Tong M, Guan XY, Lin CH, Ching YP, et al. C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget. 2016;7(17):24005\u201317.","journal-title":"Oncotarget"},{"issue":"28","key":"3873_CR35","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1038\/s41388-021-01905-3","volume":"40","author":"YH Lin","year":"2021","unstructured":"Lin YH, Wu MH, Liu YC, Lyu PC, Yeh CT, Lin KH. LINC01348 suppresses hepatocellular carcinoma metastasis through Inhibition of SF3B3-mediated EZH2 pre-mRNA splicing. Oncogene. 2021;40(28):4675\u201385.","journal-title":"Oncogene"},{"issue":"8","key":"3873_CR36","doi-asserted-by":"publisher","first-page":"e0270273","DOI":"10.1371\/journal.pone.0270273","volume":"17","author":"A Hyrina","year":"2022","unstructured":"Hyrina A, Burdette D, Song Z, Ramirez R, Okesli-Armlovich A, Vijayakumar A, et al. Targeting lipid biosynthesis pathways for hepatitis B virus cure. PLoS ONE. 2022;17(8):e0270273.","journal-title":"PLoS ONE"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03873-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T12:09:23Z","timestamp":1750507763000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03873-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3873"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03873-0","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All assays were conducted in accordance with the approval granted by the Medical Ethics and Human Clinical Trial Committee at Chang Gung Memorial Hospital (IRB: 202200859B0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}